euro adhoc: OMV Aktiengesellschaft / Interim Announcement
Further inquiry note: Branche: Oil & Gas - Downstream activities ISIN: AT0000743059 WKN: 874341 Index: ATX Prime, ATX Börsen: Wiener Börse AG / official dealing ...
mehr
Ergebnis der Suchanfrage nach @r@Borna@dokument
Inhalte
- Kategorie:
- Sprache:
-
Medien:
Alle
- Zeitraum:
- Zeitraum:Gesamt
664 Treffer
Telmisartan (MICARDIS(R)) as Effective as Ramipril But With Better Long-Term Tolerability in High-Risk Cardiovascular Asian Patients
Beijing (ots/PRNewswire) - New results from the landmark ONTARGET(R) Trial show that, in Asian patients at high risk of cardiovascular disease (CVD), telmisartan (MICARDIS(R)) 80mg is as effective as, and significantly better tolerated than, ramipril 10mg in reducing the risk of cardiovascular death, heart attack, ...
mehrFrom Curiosity to Discovery: Boehringer Ingelheim's Pipeline Update Unveils Novel Investigational Compounds Heralding the Company's Entry Into Type 2 Diabetes
Ingelheim and Biberach, Germany (ots/PRNewswire) - - Boehringer Ingelheim Oncology Pipeline Advances: Two Leading Compounds are Entering Phase III Trials - Boehringer Ingelheim's Investigational Compound in Development for the Treatment of Pre-Menopausal Women Suffering From Hypoactive Sexual Desire Disorder (HSDD) ...
mehrRecent Research Shows Significant Benefits in Acute Ischaemic Stroke With Actilyse(R) Beyond Currently Approved Three Hour Treatment Window
Ingelheim, Germany (ots/PRNewswire) - - For Healthcare Media Outside the U.S.A., Canada, and Japan - Favourable Safety and Efficacy Profile of Actilyse(R) Confirmed by ECASS 3 Study Investigating Treatment in an Extended Time Window up to 4.5 Hours After Symptom Onset First results from ECASS 3 (European Cooperative ...
mehrChange-over of CEAG AG Board of Directors
Felix Zimmermann to become sole CEO of power supply and charger manufacturer -Lonng-term Chairman and CEO Rolf Endress and CFO Frank Gumbinger leave the company by mutual consent Change due to new size and focus of CEAG Further inquiry note: Gudrun Richter Investor Relations Telefon: +49 (0) 2532-81-158 E-Mail: richter@friwo.de Branche: Semiconductors & active components ISIN: DE0006201106 WKN: 620110 Index: CDAX ...
mehrFirst Landmark ARB Trial Against Placebo Shows MICARDIS(R) (Telmisartan) Reduces the Risk of Cardiovascular Death, Heart Attack and Stroke in ACE-Intolerant High-Risk Patients(1)
Munich, Germany (ots/PRNewswire) - - TRANSCEND(R), Parallel Trial to ONTARGET(R), Confirms Long-Term Protective Benefits and Excellent Tolerability Profile of Telmisartan 80mg(1) on Top of Current Best Standard of Care MUNICH, Germany, August 31 /PRNewswire/ -- - For non-US Healthcare Media The results of the ...
mehr
euro adhoc: Mergers - Acquisitions - Takeovers / PALFINGER AG - Company Takeover/aerial working platforms
Further inquiry note: Hannes Roither, PALFINGER AG Company Spokesperson Phone +43 662 46 84-2260 mailto: h.roither@palfinger.com www.palfinger.com Branche: Machine Manufacturing ISIN: AT0000758305 WKN: 919964 Index: ATX Prime, ATX Börsen: Wiener Börse AG / official market ...
mehrMICARDIS(R)- Based Regimens Help More Patients Achieve Their Blood Pressure Goals
Berlin (ots/PRNewswire) - - For non-US Healthcare Media and non-UK Healthcare Media - New Studies Show Benefits of MICARDIS(R) (Telmisartan) in Combination With Amlodipine and Hydrochlorothiazide The results of two new studies of MICARDIS(R) (telmisartan) in free combination with amlodipine or fixed combination with hydrochlorothiazide (HCTZ) 25 mg confirm that a ...
mehrNew Data Shows Pramipexole (Mirapexin(R)/Sifrol(R)) Can Significantly Reduce Limb Pain in Patients With Restless Legs Syndrome (RLS)
Ingelheim, Germany (ots/PRNewswire) - - First Ever Study to Demonstrate Efficacy of Pramipexole in Treating RLS-Associated Limb Pain - For Healthcare Media Outside the U.S.A. A new study demonstrating that pramipexole (Mirapexin(R)/Sifrol(R)) can significantly reduce RLS-associated limb pain in patients with ...
mehrLeading Analyst Firm rates USU Valuemation in the area of IT Asset Management as "promising"
Further inquiry note: USU AG Internationalization & Partner, Marc Kothé, Phone.: +49.69.430 53 644 , Mobile: +49.173.310 3435 , Fax: +49.69.430 53 645, m.kothe@usu.de Corporate Communications, Dr. Thomas Gerick, Phone.: +49.7141.4867-440 , Mobile: +49.178.555.6664 , Fax: +49.7141.4867-909, t.gerick@usu.de http://www.usu-ag.com (english) , http://www.usu.de ...
mehreuro adhoc: OMV Aktiengesellschaft / Interim Announcement
Further inquiry note: Branche: Oil & Gas - Downstream activities ISIN: AT0000743059 WKN: 874341 Index: ATX Prime, ATX Börsen: Wiener Börse AG / official dealing ...
mehrElringKlinger lifts stake in Marusan Corporation to 50%
Further inquiry note: Stephan Haas Investor Relations Manager Telefon: +49(0)7123 724-137 E-Mail: stephan.haas@elringklinger.de Branche: Automotive Equipment ISIN: DE0007856023 WKN: 785602 Index: SDAX, CDAX, Classic All Share, Prime All Share Börsen: Börse Frankfurt / regulated dealing/prime standard Börse Berlin / free trade Börse Düsseldorf / free trade Börse München / free trade Börse Stuttgart / regulated ...
mehr
euro adhoc: Software AG / Management Changes / Software AG: Changes to the Executive Board
Further inquiry note: Otmar F. Winzig Vice President Investor Relations & Compliance Phone: +49 6151 92 1669 Email: otmar.winzig@softwareag.com Norbert Eder Vice President Corporate Communications Phone: +49 6151 92 1146 Email: norbert.eder@softwareag.com Branche: Software ISIN: DE0003304002 WKN: 330400 Index: TecDAX, CDAX, HDAX, Prime All Share, Technologie All ...
mehrData Suggests Promising Overall Survival and Progression-Free Survival With VARGATEF(TM) (BIBF 1120)
Ingelheim, Germany (ots/PRNewswire) - - For non-US Healthcare Media - Abstract # 163O. von Pawel. Proffered Papers 6 - Advanced NSCLC - Latest Phase II Data for Boehringer Ingelheim's New Cancer Drug in Development Presented Monotherapy treatment with the triple angiokinase inhibitor(1) BIBF 1120 (planned tradename ...
mehrNew Data Confirm Pramipexole (Mirapexin(R)/Sifrol(R)) Can Significantly Reduce Sleep Disturbance for People With Restless Legs Syndrome (RLS)
Ingelheim, Germany (ots/PRNewswire) - - For Healthcare Media Outside the U.S.A. - Studies Demonstrate Positive and Rapid Impact of Pramipexole on the Core Symptoms of Restless Legs Syndrome and Sleep Disturbance A new study has shown that pramipexole (Mirapexin(R)/Sifrol(R)) can significantly reduce sleep ...
mehrNew Powerful Antihypertensive MicardisPlus(R) 80/25 (80mg telmisartan/25mg hydrochlorothiazide) Approved by EU Commission
Ingelheim, Germany (ots/PRNewswire) - - For Medical Media, Outside the US Only Boehringer Ingelheim today announced that the European Commission has granted marketing authorisation of the new powerful strength of their fixed dose combination antihypertensive drug MicardisPlus(R) 80/25 in all 27 EU member states. It ...
mehrLandmark Trial ONTARGET(R) Proves Telmisartan is as Protective as Ramipril and Better Tolerated in a Broad High-Risk Cardiovascular Population. From ONTARGET(R) it May be Concluded That Telmisartan can Prevent Every 5th Serious Cardiovascular Event
Ingelheim, Germany (ots/PRNewswire) - - Results of 25,620 Patient Study ONTARGET(R) (ONgoing Telmisartan Alone and in Combination With Ramipril Global Endpoint Trial) Presented Today at the 57th Annual Scientific Session of the American College of Cardiology(1) - For Non-US Healthcare Media The results of the ...
mehreuro adhoc: Fielmann AG / Financial Figures/Balance Sheet / Pre-tax profit for the year: up 27 percent Dividend: up 17 percent to EUR 1.40 per share Employees: 698 additional jobs created
Further inquiry note: Ulrich Brockmann, Head of Investor Relations, tel: +49 40 270 76 - 442 Branche: Retail ISIN: DE0005772206 WKN: 577220 Index: SDAX, CDAX, Classic All Share, Prime All Share Börsen: Börse Frankfurt / regulated dealing/prime standard Börse Stuttgart / free trade Börse Berlin / regulated ...
mehr
euro adhoc: OMV Aktiengesellschaft / Financial Figures/Balance Sheet / Report January - December and Q4 2007: Another year of excellent results driven by strong underlying performance in all businesses
Further inquiry note: OMV Investor Relations: Ana-Barbara Kuncic Tel. +43 1 40 440-21443; e-mail: investor.relations@omv.com Press: Bettina Gneisz-Al-Ani Tel. +43 1 40 440-21660; e-mail: bettina.gneisz@omv.com Thomas Huemer Tel. +43 1 40 440-21660; e-mail: thomas.huemer@omv.com Internet Homepage: ...
mehreuro adhoc: ElringKlinger AG / Mergers - Acquisitions - Takeovers / ElringKlinger close to signing deal for takeover of Swiss heat shield specialist SEVEX AG
Further inquiry note: ElringKlinger AG Kathrin Müller Tel. +49 (0) 7123/724-631 kathrin.mueller@elringklinger.de Branche: Automotive Equipment ISIN: DE0007856023 WKN: 785602 Index: SDAX, CDAX, Classic All Share, Prime All Share Börsen: Börse Frankfurt / regulated dealing/prime standard Börse Berlin / free ...
mehreuro adhoc: OMV Aktiengesellschaft / quarterly or semiannual financial statement / Report January - September and Q3 2007 including interim financial statements as of September 30, 2007: Record result in Q3/07 with strong growth in all businesses
Disclosure announcement transmitted by euro adhoc. The issuer is responsible for the content of this announcement. 9-month report/OMV/Oil/Gas/Austria 15.11.2007 - Clean net income after minorities of EUR 489 mn, up 22% against Q3/06; strong contribution from Borealis and Petrol Ofisi and lower effective ...
mehreuro adhoc: Mergers - Acquisitions - Takeovers / PALFINGER - Acquisition of MBB Liftsystems AG
Disclosure announcement transmitted by euro adhoc. The issuer is responsible for the content of this announcement. Company Information/Übernahme 29.10.2007 Adhoc - R E L E A S E PALFINGER takes over one of the global leaders in tail lift manufacturing o 100 percent acquisition of MBB Liftsystems AG o Considerable strengthening of the TAIL LIFT product ...
mehrNew Three-Year Data Confirms Aptivus(R) (tipranavir) as Effective and Durable Treatment Option for Treatment-Experienced Patients
Madrid, Spain (ots/PRNewswire) - - For Non-U.S. Media New data from the combined RESIST studies (RESIST-1 and RESIST-2) show that Aptivus(R) (tipranavir), used with Norvir (ritonavir), provides a superior and durable treatment response for up to three years in treatment- experienced HIV patients versus ...
mehrBoehringer Ingelheim to Initiate First Phase III Pivotal Study for New Oncology Compound BIBW 2992(i)
Ingelheim, Germany (ots/PRNewswire) - - New Data on BIBW 2992(i), a Potent, Irreversible, Second-Generation Oral Signal Transduction Inhibitor Provides Glimpse of Next Chapter in Lung Cancer Care - For Non-US Media Boehringer Ingelheim announced today from the 12th World Conference on Lung Cancer (WCLC) that the company plans to commence Phase III ...
mehr
Suffering in Silence - The Real Impact of the Last Taboo
Ingelheim, Germany (ots/PRNewswire) - Constipation is a condition that we are all familiar with, however, according to new international research from Dulcolax(R), constipation actually affects much more than just bowel movements and can have a severely detrimental impact on people's quality of life, in some cases comparable to that experienced by people suffering from more serious ailments. The Dulcolax(R) survey ...
mehrCasio Introduces Two Stylish EXILIM(R) Digital Cameras with YouTube[TM] Capture Mode
Norderstedt (ots) - One with a 7x optical zoom and 8.1 megapixels, the other with high ISO 6400 sensitivity and 10.1 megapixels Casio Europe GmbH and its parent company, Casio Computer Co., Ltd., released two new EXILIM digital cameras today. The EX-V8 features a slim yet powerful optical zoom like other models in the EXILIM Hi-Zoom series, and the EX-Z1080, ...
mehrData Presented at International AIDS Society (IAS) Conference Shows Long-Term Viramune(R) (nevirapine) Efficacy and Increase in Good Cholesterol
Sydney, Australia (ots/PRNewswire) - New data from two new studies of Viramune(R) (nevirapine) were presented at the 4th International AIDS Society (IAS) in Sydney, Australia. Results from an extended three-year follow-up analysis of the 2NN study demonstrated that HIV-positive patients taking ...
mehrBoehringer Ingelheim Announces First International Head-to-Head Trial of Aptivus(R) (tipranavir) versus darunavir in Treatment-Experienced HIV-Positive Patients
Ingelheim, Germany (ots/PRNewswire) - - Trial to compare newest protease inhibitors in treatment-experienced patients with resistance to more than one PI Boehringer Ingelheim GmbH announced today that enrollment of the POTENT study will begin in August 2007. POTENT will compare the efficacy and safety ...
mehrInternational Experts and Women Living With HIV Discuss Urgent Needs of HIV-Positive Women at International AIDS Society (IAS) Congress
Sydney, Australia (ots/PRNewswire) - - Panelists Available For Interviews - For Immediate Release: Webcast Will Be Available At: Http://Link.Viostream.Com/?A02deceb-Ecf4-4d9f-9118-F5f60faef629 Women Living Positive, a roundtable discussion at the IAS congress in Sydney, featured the ...
mehrNew Study Shows That telmisartan has Greater Renoprotective Potential Than losartan in Hypertensive Patients With Type 2 Diabetes
Milan, Italy (ots/PRNewswire) - - For non-US Healthcare Media Today AMADEO, one of the first studies to compare the protective potential of two angiotensin receptor blockers in hypertensive patients with diabetic nephropathy, was presented at the European Society of Hypertension, Milan. The results from ...
mehr
Vorherige14151617181920212223Nächste